These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10536687)

  • 1. New look at myocardial infarction: toward a better aspirin.
    Bing RJ; Yamamoto T; Yamamoto M; Kakar R; Cohen A
    Cardiovasc Res; 1999 Jul; 43(1):25-31. PubMed ID: 10536687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of prostanoids and nitric oxide by infarcted heart in situ and the effect of aspirin.
    Yamamoto T; Cohen AM; Kakar NR; Yamamoto M; Johnson PE; Cho YK; Bing RJ
    Biochem Biophys Res Commun; 1999 Apr; 257(2):488-93. PubMed ID: 10198239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial ischemia and infarction: growth of ideas.
    Bing RJ
    Cardiovasc Res; 2001 Jul; 51(1):13-20. PubMed ID: 11399243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomedicine. Back to an aspirin a day?
    Vane JR
    Science; 2002 Apr; 296(5567):474-5. PubMed ID: 11964462
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of aspirin and two nitric oxide donors on the infarcted heart in situ.
    Yamamoto T; Kakar NR; Vina ER; Johnson PE; Bing RJ
    Life Sci; 2000 Jul; 67(7):839-46. PubMed ID: 10968413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin and its rivals. As your options increase, your choices get harder.
    Harv Mens Health Watch; 2002 Dec; 7(5):1-5. PubMed ID: 12499131
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ.
    Yamamoto T; Kakar NR; Vina ER; Johnson PE; Bing RJ
    Pharmacology; 2001 Jul; 63(1):28-33. PubMed ID: 11408829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
    Velázquez C; Praveen Rao PN; Knaus EE
    J Med Chem; 2005 Jun; 48(12):4061-7. PubMed ID: 15943479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction.
    Dalen JE
    Arch Intern Med; 2002 May; 162(10):1091-2. PubMed ID: 12020175
    [No Abstract]   [Full Text] [Related]  

  • 10. [Aspirin. A wonder drug?].
    Diez-Ewald M
    Invest Clin; 1997 Jun; 38(2):59-61. PubMed ID: 9296640
    [No Abstract]   [Full Text] [Related]  

  • 11. COX-2 inhibitors and metabolism of essential fatty acids.
    Das UN
    Med Sci Monit; 2005 Jul; 11(7):RA233-7. PubMed ID: 15990700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma".
    Sakata C; Kawasaki T; Kato Y; Abe M; Suzuki K; Ohmiya M; Funatsu T; Morita Y; Okada M
    Thromb Res; 2013 Jul; 132(1):56-62. PubMed ID: 23522855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What price pain relief?
    Hochman JS; Shah NR
    Circulation; 2006 Jun; 113(25):2868-70. PubMed ID: 16785335
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacological correction by roxicam of the prostacyclin-thromboxane system in acute myocardial infarction complicated by heart failure].
    Shushliapin OI; Shelest AN; Khosseĭn Shakhavat AF
    Kardiologiia; 1991 Aug; 31(8):39-41. PubMed ID: 1795470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion.
    Robich MP; Chu LM; Burgess TA; Feng J; Bianchi C; Sellke FW
    J Cardiovasc Pharmacol; 2011 Jan; 57(1):122-30. PubMed ID: 21233641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs.
    Patrono C; Patrignani P; García Rodríguez LA
    J Clin Invest; 2001 Jul; 108(1):7-13. PubMed ID: 11435450
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of aspirin in the long-term management of atherothrombosis.
    Patrono C
    Haematologica; 2002 Jan; 87(1):6-8. PubMed ID: 11801459
    [No Abstract]   [Full Text] [Related]  

  • 18. Controversies in COX-2 selective inhibition.
    Simon LS; Smolen JS; Abramson SB; Appel G; Bombardier C; Brater DC; Breedveld FC; Brune K; Burmester GR; Crofford LJ; Dougados M; DuBois RN; Fitzgerald GA; Frishman W; García Rodríguez LA; Hochberg MC; Kalden JR; Laine L; Langman MJ; Prescott SM; van de Putte LB; Whelton A; White WB; Willaims GH
    J Rheumatol; 2002 Jul; 29(7):1501-10. PubMed ID: 12136912
    [No Abstract]   [Full Text] [Related]  

  • 19. The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low?
    Förster W; Parratt JR
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):727-34. PubMed ID: 9110116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment, drug approval, and liability.
    Somberg JC
    Am J Ther; 2006; 13(3):181-2. PubMed ID: 16772756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.